[TITLE]MAAS Announces Strategic Expansion into Healthcare and Wellness with Acquisition of Carve Group Ltd:
[TEXT]
CHENGDU, China, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Maase Inc. (NASDAQ: MAAS) (“MAAS” or the “Company”) today announced the successful completion of its strategic acquisition of 100% equity interests in Carve Group Ltd (the “Target Company” or the “Carve Group”). The transaction, previously disclosed in the Company’s Form 6-K filed on July 29, 2025, was formally consummated on August 27, 2025.

Pursuant to the transaction agreement dated July 28, 2025, MAAS has acquired all equity interests in the Target Company from its existing shareholders, Golden Brighter Limited (“GBL”), WJ Management Company Limited (“WJM”), and Union Chief Limited (“UCL”) (collectively, the “Sellers”). As consideration, MAAS issued an aggregate of 195,894,609 Class A ordinary shares with a par value of US$0.09 per share (the “Consideration Shares”), at an issue price of US$1.50 per share. As of August 27, 2025 (the “Closing Date”), the Company had a total of 221,811,850 ordinary shares outstanding, consisting of 215,145,182 Class A ordinary shares and 6,666,668 Class B ordinary shares. The Sellers collectively hold 195,894,609 Class A ordinary shares of the Company, representing approximately 88.32% of the total issued share capital and approximately 22.22% of the total voting power. Among the Sellers, GBL and WJM each hold 93,049,939 shares, representing approximately 41.95% of the total issued share capital and approximately 10.55% of the total voting power, respectively. The shareholdings of GBL and WJM are subject to a five-year lock-up period. Following the acquisition, MAAS indirectly holds full ownership of Carve Group’s wholly-owned subsidiaries, Zhongshen Resources Development (Liaoning) Co., Ltd. (“Zhongshen”) and Glyken Bird Nest Technology (Shenzhen) Co., Ltd. (“Glyken”).

Zhongshen holds the land use rights for 111 mu of premium forest land in the core wild ginseng growing region of Hengren County, Liaoning Province, with over 19,000 scarce wild-grown ginseng roots aged over 40 years, establishing it as a provider of scarce upstream traditional Chinese medicine resource.

Glyken, owns the bird’s nest biotechnology factory in the Guangxi Free Trade Zone, it possesses an SC food production certification and an annual production capacity of 10 tons of bird’s nest peptides. Its product portfolio covers anti-aging, precision nutrition, functional food/beverages, and skincare, making it a benchmark in the bird’s nest biotech platform.

Leveraging Zhongshen’s scarce medicinal resources and Glyken’s biotechnology platform, MAAS will use modern biotechnology to scientifically upgrade traditional wellness products. This move establishes its presence in the healthcare and wellness space and underscores its commitment to building a globally competitive health product and service ecosystem.
[Source link]: https://www.globenewswire.com/news-release/2025/08/28/3140651/0/en/MAAS-Announces-Strategic-Expansion-into-Healthcare-and-Wellness-with-Acquisition-of-Carve-Group-Ltd.html


[TITLE]Quantbot Technologies LP Makes New Investment in National HealthCare Co. $NHC:
[TEXT]
Quantbot Technologies LP bought a new stake in National HealthCare Co. (NYSE:NHC – Free Report) during the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm bought 2,987 shares of the company’s stock, valued at approximately $277,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Northern Trust Corp boosted its position in shares of National HealthCare by 4.8% during the 4th quarter. Northern Trust Corp now owns 193,792 shares of the company’s stock worth $20,844,000 after acquiring an additional 8,795 shares in the last quarter. Alps Advisors Inc. lifted its stake in National HealthCare by 7.7% during the first quarter. Alps Advisors Inc. now owns 147,800 shares of the company’s stock worth $13,716,000 after purchasing an additional 10,614 shares during the last quarter. Systematic Financial Management LP lifted its stake in National HealthCare by 3.5% during the fourth quarter. Systematic Financial Management LP now owns 117,884 shares of the company’s stock worth $12,680,000 after purchasing an additional 3,962 shares during the last quarter. Principal Financial Group Inc. boosted its holdings in shares of National HealthCare by 2.6% in the 1st quarter. Principal Financial Group Inc. now owns 65,410 shares of the company’s stock valued at $6,070,000 after purchasing an additional 1,671 shares in the last quarter. Finally, First Trust Advisors LP increased its stake in shares of National HealthCare by 75.6% in the 4th quarter. First Trust Advisors LP now owns 47,062 shares of the company’s stock valued at $5,062,000 after purchasing an additional 20,268 shares during the last quarter. Institutional investors own 56.44% of the company’s stock.

Get National HealthCare alerts:

Analysts Set New Price Targets

Separately, Wall Street Zen upgraded National HealthCare from a “buy” rating to a “strong-buy” rating in a research note on Monday, May 12th.

National HealthCare Stock Up 0.5%

Shares of NYSE:NHC opened at $111.97 on Thursday. National HealthCare Co. has a 52-week low of $89.14 and a 52-week high of $137.53. The company has a market capitalization of $1.74 billion, a PE ratio of 14.03 and a beta of 0.58. The company has a debt-to-equity ratio of 0.14, a quick ratio of 1.77 and a current ratio of 1.80. The company has a fifty day moving average of $103.37 and a 200-day moving average of $99.37.

National HealthCare Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th will be issued a $0.64 dividend. This represents a $2.56 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date of this dividend is Tuesday, September 30th. National HealthCare’s dividend payout ratio is presently 38.15%.

About National HealthCare

(Free Report)

National HealthCare Corporation engages in the operation of services to skilled nursing facilities, assisted and independent living facilities, homecare and hospice agencies, and health hospitals. Its skilled nursing facilities offer licensed therapy services, nutrition services, social services, activities, and housekeeping and laundry services, as well as medical services prescribed by physicians; and rehabilitative services, such as physical, speech, respiratory, and occupational therapy for patients recovering from strokes, heart attacks, orthopedic conditions, neurological illnesses, or other illnesses, injuries, or disabilities.

See Also

Want to see what other hedge funds are holding NHC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for National HealthCare Co. (NYSE:NHC – Free Report).

Receive News & Ratings for National HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for National HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.
[Source link]: https://www.etfdailynews.com/2025/08/28/quantbot-technologies-lp-makes-new-investment-in-national-healthcare-co-nhc/


[TITLE]MedaSync announces strategic investment from Omega Healthcare OHI:
[TEXT]
Mon AS X AS Amer Sports

Block Trade

Managers: Morgan Stanley

Priced at: $39.90

4.05M Shares

Special Comments

Exclusive Analysis Locked Proprietary deal commentary available to members only.
[Source link]: https://thefly.com/permalinks/entry.php/id4189228/OHI-MedaSync-announces-strategic-investment-from-Omega-Healthcare


[TITLE]SCWorx Expands Healthcare Data Management Network with New Collaboration:
[TEXT]
Tampa, FL, Aug. 26, 2025 (GLOBE NEWSWIRE) -- SCWorx Corp. (Nasdaq: WORX) today announced a new agreement with a leading healthcare supply chain partner, further strengthening its SaaS data management program.

The partner is a recognized leader in healthcare supply chain consulting, with deep experience helping hospitals unlock cost savings and optimize spend management. The partner also has access to best-in-class products and services at the local, regional, and national levels for virtually every product or service to help hospitals optimize their direct and indirect procurement spend categories.

“This partner drives measurable savings by vetting vendors, analyzing contracts, and leveraging billions in spend through strategic purchasing. They have purchasing partners in all 50 states and are growing every day. All of this helps the partner anticipate, identify, and proactively deliver cost-saving opportunities through cooperative purchasing on an ongoing basis,” said Tim Hannibal, SCWorx CEO. Hannibal added, “The SCWorx Foundation product will help this partner enhance their product line and provide additional value to their healthcare customer. This partner chose SCWorx for its data cleanse, normalization and enrichment service offerings. SCWorx is a valuable data management service partner specifically built to help hospitals in the U.S. better utilize data. This partnership reinforces the unique value SCWorx delivers to hospitals nationwide.”
[Source link]: https://www.globenewswire.com/news-release/2025/08/26/3139426/0/en/SCWorx-Expands-Healthcare-Data-Management-Network-with-New-Collaboration.html

================================================================================

[TITLE]Quantbot Technologies LP Makes New Investment in National HealthCare Co. $NHC:
[TEXT]
Quantbot Technologies LP bought a new stake in National HealthCare Co. (NYSE:NHC – Free Report) during the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm bought 2,987 shares of the company’s stock, valued at approximately $277,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Northern Trust Corp boosted its position in shares of National HealthCare by 4.8% during the 4th quarter. Northern Trust Corp now owns 193,792 shares of the company’s stock worth $20,844,000 after acquiring an additional 8,795 shares in the last quarter. Alps Advisors Inc. lifted its stake in National HealthCare by 7.7% during the first quarter. Alps Advisors Inc. now owns 147,800 shares of the company’s stock worth $13,716,000 after purchasing an additional 10,614 shares during the last quarter. Systematic Financial Management LP lifted its stake in National HealthCare by 3.5% during the fourth quarter. Systematic Financial Management LP now owns 117,884 shares of the company’s stock worth $12,680,000 after purchasing an additional 3,962 shares during the last quarter. Principal Financial Group Inc. boosted its holdings in shares of National HealthCare by 2.6% in the 1st quarter. Principal Financial Group Inc. now owns 65,410 shares of the company’s stock valued at $6,070,000 after purchasing an additional 1,671 shares in the last quarter. Finally, First Trust Advisors LP increased its stake in shares of National HealthCare by 75.6% in the 4th quarter. First Trust Advisors LP now owns 47,062 shares of the company’s stock valued at $5,062,000 after purchasing an additional 20,268 shares during the last quarter. Institutional investors own 56.44% of the company’s stock.

Get National HealthCare alerts:

Analysts Set New Price Targets

Separately, Wall Street Zen upgraded National HealthCare from a “buy” rating to a “strong-buy” rating in a research note on Monday, May 12th.

National HealthCare Stock Up 0.5%

Shares of NYSE:NHC opened at $111.97 on Thursday. National HealthCare Co. has a 52-week low of $89.14 and a 52-week high of $137.53. The company has a market capitalization of $1.74 billion, a PE ratio of 14.03 and a beta of 0.58. The company has a debt-to-equity ratio of 0.14, a quick ratio of 1.77 and a current ratio of 1.80. The company has a fifty day moving average of $103.37 and a 200-day moving average of $99.37.

National HealthCare Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th will be issued a $0.64 dividend. This represents a $2.56 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date of this dividend is Tuesday, September 30th. National HealthCare’s dividend payout ratio is presently 38.15%.

About National HealthCare

(Free Report)

National HealthCare Corporation engages in the operation of services to skilled nursing facilities, assisted and independent living facilities, homecare and hospice agencies, and health hospitals. Its skilled nursing facilities offer licensed therapy services, nutrition services, social services, activities, and housekeeping and laundry services, as well as medical services prescribed by physicians; and rehabilitative services, such as physical, speech, respiratory, and occupational therapy for patients recovering from strokes, heart attacks, orthopedic conditions, neurological illnesses, or other illnesses, injuries, or disabilities.

See Also

Want to see what other hedge funds are holding NHC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for National HealthCare Co. (NYSE:NHC – Free Report).

Receive News & Ratings for National HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for National HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.
[Source link]: https://www.etfdailynews.com/2025/08/28/quantbot-technologies-lp-makes-new-investment-in-national-healthcare-co-nhc/


[TITLE]MedaSync announces strategic investment from Omega Healthcare OHI:
[TEXT]
Mon AS X AS Amer Sports

Block Trade

Managers: Morgan Stanley

Priced at: $39.90

4.05M Shares

Special Comments

Exclusive Analysis Locked Proprietary deal commentary available to members only.
[Source link]: https://thefly.com/permalinks/entry.php/id4189228/OHI-MedaSync-announces-strategic-investment-from-Omega-Healthcare


[TITLE]Quantbot Technologies LP Invests $554,000 in Healthcare Services Group, Inc. $HCSG:
[TEXT]
Quantbot Technologies LP bought a new position in Healthcare Services Group, Inc. (NASDAQ:HCSG – Free Report) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 54,967 shares of the business services provider’s stock, valued at approximately $554,000. Quantbot Technologies LP owned approximately 0.08% of Healthcare Services Group at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of HCSG. US Bancorp DE lifted its holdings in Healthcare Services Group by 161.4% during the 1st quarter. US Bancorp DE now owns 8,097 shares of the business services provider’s stock worth $82,000 after buying an additional 5,000 shares in the last quarter. PharVision Advisers LLC acquired a new position in Healthcare Services Group during the 4th quarter worth $147,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in Healthcare Services Group by 45.3% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,592 shares of the business services provider’s stock worth $147,000 after buying an additional 4,548 shares in the last quarter. Dark Forest Capital Management LP acquired a new position in Healthcare Services Group during the 4th quarter worth $158,000. Finally, MQS Management LLC acquired a new position in Healthcare Services Group during the 1st quarter worth $173,000. Institutional investors and hedge funds own 97.97% of the company’s stock.

Get Healthcare Services Group alerts:

Wall Street Analysts Forecast Growth

HCSG has been the topic of several research reports. Macquarie raised Healthcare Services Group from a “neutral” rating to an “outperform” rating and upped their price objective for the stock from $15.00 to $16.00 in a report on Tuesday, July 29th. Benchmark upped their price objective on Healthcare Services Group from $17.00 to $19.00 and gave the stock a “buy” rating in a report on Thursday, July 24th. Wall Street Zen cut shares of Healthcare Services Group from a “strong-buy” rating to a “buy” rating in a research report on Saturday, July 26th. Robert W. Baird upped their target price on shares of Healthcare Services Group from $13.00 to $15.00 and gave the company a “neutral” rating in a research report on Thursday, July 24th. Finally, Zacks Research upgraded shares of Healthcare Services Group to a “strong-buy” rating in a research report on Tuesday, August 12th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, Healthcare Services Group has an average rating of “Buy” and a consensus target price of $16.25.

Insider Buying and Selling

In related news, EVP John Christopher Shea sold 21,368 shares of the firm’s stock in a transaction on Monday, July 28th. The stock was sold at an average price of $13.25, for a total transaction of $283,126.00. Following the sale, the executive vice president owned 32,976 shares of the company’s stock, valued at approximately $436,932. This trade represents a 39.32% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 2.10% of the company’s stock.

Healthcare Services Group Trading Down 1.8%

Shares of Healthcare Services Group stock opened at $15.49 on Tuesday. The company has a market capitalization of $1.12 billion, a PE ratio of 110.64 and a beta of 0.54. Healthcare Services Group, Inc. has a 12 month low of $9.13 and a 12 month high of $15.89. The stock’s fifty day simple moving average is $14.29 and its 200 day simple moving average is $12.81.

Healthcare Services Group (NASDAQ:HCSG – Get Free Report) last issued its quarterly earnings data on Wednesday, July 23rd. The business services provider reported $0.21 EPS for the quarter, topping the consensus estimate of $0.20 by $0.01. The business had revenue of $458.50 million for the quarter, compared to the consensus estimate of $450.78 million. Healthcare Services Group had a return on equity of 11.74% and a net margin of 0.61%.The firm’s revenue was up 7.6% compared to the same quarter last year. During the same quarter last year, the business posted $0.20 EPS. Healthcare Services Group has set its Q3 2025 guidance at EPS. Analysts predict that Healthcare Services Group, Inc. will post 0.74 EPS for the current fiscal year.
[Source link]: https://www.etfdailynews.com/2025/08/26/quantbot-technologies-lp-invests-554000-in-healthcare-services-group-inc-hcsg/


[TITLE]Charles Schwab Investment Management Inc. Acquires 74,476 Shares of Healthcare Services Group, Inc. $HCSG:
[TEXT]
Charles Schwab Investment Management Inc. raised its holdings in Healthcare Services Group, Inc. (NASDAQ:HCSG – Free Report) by 8.4% in the 1st quarter, HoldingsChannel reports. The fund owned 965,843 shares of the business services provider’s stock after acquiring an additional 74,476 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Healthcare Services Group were worth $9,736,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of the business. Royce & Associates LP grew its stake in shares of Healthcare Services Group by 0.3% in the first quarter. Royce & Associates LP now owns 4,684,038 shares of the business services provider’s stock worth $47,215,000 after purchasing an additional 15,439 shares during the last quarter. Mackenzie Financial Corp raised its position in Healthcare Services Group by 0.8% during the 1st quarter. Mackenzie Financial Corp now owns 4,128,934 shares of the business services provider’s stock worth $41,620,000 after purchasing an additional 34,037 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in Healthcare Services Group by 9.0% during the 4th quarter. Dimensional Fund Advisors LP now owns 2,523,745 shares of the business services provider’s stock worth $29,313,000 after buying an additional 208,810 shares during the period. Palisade Capital Management LP grew its position in shares of Healthcare Services Group by 0.9% in the 1st quarter. Palisade Capital Management LP now owns 2,237,866 shares of the business services provider’s stock valued at $22,558,000 after buying an additional 20,720 shares during the last quarter. Finally, Janus Henderson Group PLC grew its position in shares of Healthcare Services Group by 12.5% in the 4th quarter. Janus Henderson Group PLC now owns 1,266,785 shares of the business services provider’s stock valued at $14,714,000 after buying an additional 140,708 shares during the last quarter. Institutional investors own 97.97% of the company’s stock.

Get Healthcare Services Group alerts:

Healthcare Services Group Stock Up 3.6%

Healthcare Services Group stock opened at $15.77 on Monday. The company has a market capitalization of $1.14 billion, a PE ratio of 112.64 and a beta of 0.54. Healthcare Services Group, Inc. has a 12-month low of $9.13 and a 12-month high of $15.80. The firm’s fifty day moving average is $14.28 and its 200 day moving average is $12.77.

Insider Buying and Selling

Healthcare Services Group ( NASDAQ:HCSG Get Free Report ) last posted its quarterly earnings results on Wednesday, July 23rd. The business services provider reported $0.21 earnings per share for the quarter, beating the consensus estimate of $0.20 by $0.01. Healthcare Services Group had a net margin of 0.61% and a return on equity of 11.74%. The firm had revenue of $458.50 million during the quarter, compared to the consensus estimate of $450.78 million. During the same period in the previous year, the firm posted $0.20 earnings per share. The business’s revenue was up 7.6% compared to the same quarter last year. Healthcare Services Group has set its Q3 2025 guidance at EPS. Sell-side analysts expect that Healthcare Services Group, Inc. will post 0.74 EPS for the current fiscal year.

In related news, EVP John Christopher Shea sold 21,368 shares of the company’s stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $13.25, for a total transaction of $283,126.00. Following the transaction, the executive vice president directly owned 32,976 shares of the company’s stock, valued at approximately $436,932. This represents a 39.32% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 2.10% of the stock is owned by insiders.

Analyst Ratings Changes

HCSG has been the subject of a number of analyst reports. Robert W. Baird raised their price objective on Healthcare Services Group from $13.00 to $15.00 and gave the stock a “neutral” rating in a research report on Thursday, July 24th. Zacks Research raised shares of Healthcare Services Group to a “strong-buy” rating in a research report on Tuesday, August 12th. Wall Street Zen downgraded shares of Healthcare Services Group from a “strong-buy” rating to a “buy” rating in a research report on Saturday, July 26th. Benchmark upped their price objective on shares of Healthcare Services Group from $17.00 to $19.00 and gave the company a “buy” rating in a research note on Thursday, July 24th. Finally, Macquarie raised shares of Healthcare Services Group from a “neutral” rating to an “outperform” rating and lifted their target price for the stock from $15.00 to $16.00 in a research note on Tuesday, July 29th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Healthcare Services Group has an average rating of “Buy” and an average target price of $16.25.

Get Our Latest Stock Report on HCSG

Healthcare Services Group Profile

(Free Report)

Healthcare Services Group, Inc provides management, administrative, and operating services to the housekeeping, laundry, linen, facility maintenance, and dietary service departments of nursing homes, retirement complexes, rehabilitation centers, and hospitals in the United States. It operates through two segments, Housekeeping and Dietary.

Read More

Want to see what other hedge funds are holding HCSG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Healthcare Services Group, Inc. (NASDAQ:HCSG – Free Report).

Receive News & Ratings for Healthcare Services Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Healthcare Services Group and related companies with MarketBeat.com's FREE daily email newsletter.
[Source link]: https://www.etfdailynews.com/2025/08/25/charles-schwab-investment-management-inc-acquires-74476-shares-of-healthcare-services-group-inc-hcsg/

================================================================================

[Failed to load article at https://consent.yahoo.com/v2/collectConsent?sessionId=1_cc-session_f4361755-96d5-4bdf-a572-313aa5030e86]


[TITLE]Nuveen LLC Makes New Investment in Terns Pharmaceuticals, Inc. $TERN:
[TEXT]
Nuveen LLC bought a new stake in Terns Pharmaceuticals, Inc. (NASDAQ:TERN – Free Report) in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 1,405,901 shares of the company’s stock, valued at approximately $3,880,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in TERN. Thrive Wealth Management LLC acquired a new position in shares of Terns Pharmaceuticals in the first quarter valued at approximately $29,000. Vontobel Holding Ltd. acquired a new stake in Terns Pharmaceuticals during the 1st quarter worth approximately $39,000. Velan Capital Investment Management LP bought a new stake in Terns Pharmaceuticals during the 4th quarter worth approximately $94,000. Sherbrooke Park Advisers LLC bought a new stake in Terns Pharmaceuticals during the 4th quarter worth approximately $99,000. Finally, Invesco Ltd. grew its holdings in Terns Pharmaceuticals by 13.3% during the 4th quarter. Invesco Ltd. now owns 23,400 shares of the company’s stock worth $130,000 after acquiring an additional 2,753 shares during the last quarter. 98.26% of the stock is currently owned by institutional investors.

Get Terns Pharmaceuticals alerts:

Terns Pharmaceuticals Price Performance

TERN opened at $6.89 on Thursday. Terns Pharmaceuticals, Inc. has a fifty-two week low of $1.87 and a fifty-two week high of $11.40. The company’s 50 day moving average price is $5.45 and its two-hundred day moving average price is $3.99. The firm has a market capitalization of $602.94 million, a price-to-earnings ratio of -6.63 and a beta of -0.05.

Insider Activity at Terns Pharmaceuticals

Terns Pharmaceuticals ( NASDAQ:TERN Get Free Report ) last released its quarterly earnings results on Tuesday, August 5th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.28) by $0.02. As a group, equities research analysts predict that Terns Pharmaceuticals, Inc. will post -1.19 EPS for the current year.

In other news, CEO Amy L. Burroughs purchased 23,314 shares of the stock in a transaction on Wednesday, June 25th. The stock was purchased at an average price of $3.87 per share, for a total transaction of $90,225.18. Following the acquisition, the chief executive officer owned 47,083 shares in the company, valued at $182,211.21. This trade represents a 98.09% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Andrew Gengos purchased 10,000 shares of the stock in a transaction on Friday, June 27th. The shares were purchased at an average price of $3.93 per share, with a total value of $39,300.00. Following the acquisition, the chief financial officer owned 25,000 shares in the company, valued at approximately $98,250. The trade was a 66.67% increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders have acquired 48,314 shares of company stock valued at $186,575. Company insiders own 1.50% of the company’s stock.

Wall Street Analyst Weigh In

Separately, BMO Capital Markets reduced their target price on shares of Terns Pharmaceuticals from $26.00 to $15.00 and set an “outperform” rating on the stock in a report on Tuesday, May 13th. Three analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $15.63.

View Our Latest Stock Report on Terns Pharmaceuticals

Terns Pharmaceuticals Profile

(Free Report)

Terns Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow.

Featured Stories

Want to see what other hedge funds are holding TERN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Terns Pharmaceuticals, Inc. (NASDAQ:TERN – Free Report).

Receive News & Ratings for Terns Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Terns Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
[Source link]: https://www.etfdailynews.com/2025/08/28/nuveen-llc-makes-new-investment-in-terns-pharmaceuticals-inc-tern/


[TITLE]AbbVie to Acquire Gilgamesh Pharmaceuticals' Bretisilocin, a Novel, Investigational Therapy for Major Depressive Disorder, Expanding Psychiatry Pipeline:
[TEXT]
NORTH CHICAGO, Ill. and NEW YORK, Aug. 25, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Gilgamesh Pharmaceuticals Inc. ("Gilgamesh") today announced a definitive agreement under which AbbVie will acquire Gilgamesh's lead investigational candidate, currently in clinical development for the…

This story appeared on news.abbvie.com , 2025-08-25 14:52:27.963000.
[Source link]: https://biztoc.com/x/f90a0380efe821c8


[TITLE]American Century Companies Inc. Increases Stake in Centessa Pharmaceuticals PLC Sponsored ADR $CNTA:
[TEXT]
American Century Companies Inc. boosted its position in shares of Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA – Free Report) by 1.2% during the 1st quarter, according to its most recent 13F filing with the SEC. The fund owned 1,092,754 shares of the company’s stock after purchasing an additional 13,046 shares during the quarter. American Century Companies Inc.’s holdings in Centessa Pharmaceuticals were worth $15,714,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of CNTA. Janus Henderson Group PLC grew its position in Centessa Pharmaceuticals by 279.2% during the 4th quarter. Janus Henderson Group PLC now owns 4,909,487 shares of the company’s stock valued at $82,218,000 after purchasing an additional 3,614,623 shares during the last quarter. Foresite Capital Management VI LLC purchased a new stake in Centessa Pharmaceuticals during the 4th quarter valued at
[Source link]: https://www.etfdailynews.com/2025/08/25/american-century-companies-inc-increases-stake-in-centessa-pharmaceuticals-plc-sponsored-adr-cnta/

================================================================================

[TITLE]Brooklyn Investment Group Makes New Investment in Sana Biotechnology, Inc. $SANA:
[TEXT]
Brooklyn Investment Group purchased a new position in shares of Sana Biotechnology, Inc. (NASDAQ:SANA – Free Report) during the first quarter, Holdings Channel.com reports. The firm purchased 25,943 shares of the company’s stock, valued at approximately $44,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of SANA. Geode Capital Management LLC boosted its holdings in shares of Sana Biotechnology by 0.8% during the 4th quarter. Geode Capital Management LLC now owns 3,193,081 shares of the company’s stock worth $5,206,000 after buying an additional 26,601 shares in the last quarter. Wells Fargo & Company MN boosted its holdings in shares of Sana Biotechnology by 51.0% during the 4th quarter. Wells Fargo & Company MN now owns 62,021 shares of the company’s stock worth $101,000 after buying an additional 20,950 shares in the last quarter. Cerity Partners LLC bought a new position in shares of Sana Biotechnology during the 4th quarter worth approximately $25,000. Renaissance Technologies LLC boosted its holdings in shares of Sana Biotechnology by 1,838.3% during the 4th quarter. Renaissance Technologies LLC now owns 319,818 shares of the company’s stock worth $521,000 after buying an additional 303,318 shares in the last quarter. Finally, Walleye Capital LLC bought a new position in shares of Sana Biotechnology during the 4th quarter worth approximately $152,000. 88.23% of the stock is currently owned by institutional investors.

Get Sana Biotechnology alerts:

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on SANA. JMP Securities reiterated a “market outperform” rating and issued a $5.00 target price on shares of Sana Biotechnology in a report on Tuesday, June 24th. Morgan Stanley began coverage on Sana Biotechnology in a report on Thursday, July 3rd. They issued an “overweight” rating and a $12.00 target price on the stock. Six research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $8.00.

Sana Biotechnology Stock Down 0.6%

Shares of SANA opened at $3.58 on Friday. Sana Biotechnology, Inc. has a 12-month low of $1.26 and a 12-month high of $7.30. The business’s fifty day moving average is $3.64 and its 200 day moving average is $2.70. The stock has a market cap of $851.36 million, a P/E ratio of -3.38 and a beta of 1.90.

Sana Biotechnology (NASDAQ:SANA – Get Free Report) last released its quarterly earnings results on Monday, August 11th. The company reported ($0.16) EPS for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.04. On average, analysts expect that Sana Biotechnology, Inc. will post -1.16 EPS for the current year.
[Source link]: https://www.etfdailynews.com/2025/08/24/brooklyn-investment-group-makes-new-investment-in-sana-biotechnology-inc-sana/


[TITLE]Vanguard Group Inc. Reduces Stake in Vir Biotechnology, Inc. $VIR:
[TEXT]
Vanguard Group Inc. lessened its position in shares of Vir Biotechnology, Inc. (NASDAQ:VIR – Free Report) by 2.5% in the first quarter, Holdings Channel reports. The fund owned 12,807,508 shares of the company’s stock after selling 323,127 shares during the quarter. Vanguard Group Inc. owned
[Source link]: https://www.etfdailynews.com/2025/08/24/vanguard-group-inc-reduces-stake-in-vir-biotechnology-inc-vir/

================================================================================

[TITLE]MAAS Announces Strategic Expansion into Healthcare and Wellness with Acquisition of Carve Group Ltd:
[TEXT]
CHENGDU, China, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Maase Inc. (NASDAQ: MAAS) (“MAAS” or the “Company”) today announced the successful completion of its strategic acquisition of 100% equity interests in Carve Group Ltd (the “Target Company” or the “Carve Group”). The transaction, previously disclosed in the Company’s Form 6-K filed on July 29, 2025, was formally consummated on August 27, 2025.

Pursuant to the transaction agreement dated July 28, 2025, MAAS has acquired all equity interests in the Target Company from its existing shareholders, Golden Brighter Limited (“GBL”), WJ Management Company Limited (“WJM”), and Union Chief Limited (“UCL”) (collectively, the “Sellers”). As consideration, MAAS issued an aggregate of 195,894,609 Class A ordinary shares with a par value of US$0.09 per share (the “Consideration Shares”), at an issue price of US$1.50 per share. As of August 27, 2025 (the “Closing Date”), the Company had a total of 221,811,850 ordinary shares outstanding, consisting of 215,145,182 Class A ordinary shares and 6,666,668 Class B ordinary shares. The Sellers collectively hold 195,894,609 Class A ordinary shares of the Company, representing approximately 88.32% of the total issued share capital and approximately 22.22% of the total voting power. Among the Sellers, GBL and WJM each hold 93,049,939 shares, representing approximately 41.95% of the total issued share capital and approximately 10.55% of the total voting power, respectively. The shareholdings of GBL and WJM are subject to a five-year lock-up period. Following the acquisition, MAAS indirectly holds full ownership of Carve Group’s wholly-owned subsidiaries, Zhongshen Resources Development (Liaoning) Co., Ltd. (“Zhongshen”) and Glyken Bird Nest Technology (Shenzhen) Co., Ltd. (“Glyken”).

Zhongshen holds the land use rights for 111 mu of premium forest land in the core wild ginseng growing region of Hengren County, Liaoning Province, with over 19,000 scarce wild-grown ginseng roots aged over 40 years, establishing it as a provider of scarce upstream traditional Chinese medicine resource.

Glyken, owns the bird’s nest biotechnology factory in the Guangxi Free Trade Zone, it possesses an SC food production certification and an annual production capacity of 10 tons of bird’s nest peptides. Its product portfolio covers anti-aging, precision nutrition, functional food/beverages, and skincare, making it a benchmark in the bird’s nest biotech platform.

Leveraging Zhongshen’s scarce medicinal resources and Glyken’s biotechnology platform, MAAS will use modern biotechnology to scientifically upgrade traditional wellness products. This move establishes its presence in the healthcare and wellness space and underscores its commitment to building a globally competitive health product and service ecosystem.
[Source link]: https://www.globenewswire.com/news-release/2025/08/28/3140651/0/en/MAAS-Announces-Strategic-Expansion-into-Healthcare-and-Wellness-with-Acquisition-of-Carve-Group-Ltd.html


[TITLE]Quantbot Technologies LP Makes New Investment in National HealthCare Co. $NHC:
[TEXT]
Quantbot Technologies LP bought a new stake in National HealthCare Co. (NYSE:NHC – Free Report) during the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm bought 2,987 shares of the company’s stock, valued at approximately $277,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Northern Trust Corp boosted its position in shares of National HealthCare by 4.8% during the 4th quarter. Northern Trust Corp now owns 193,792 shares of the company’s stock worth $20,844,000 after acquiring an additional 8,795 shares in the last quarter. Alps Advisors Inc. lifted its stake in National HealthCare by 7.7% during the first quarter. Alps Advisors Inc. now owns 147,800 shares of the company’s stock worth $13,716,000 after purchasing an additional 10,614 shares during the last quarter. Systematic Financial Management LP lifted its stake in National HealthCare by 3.5% during the fourth quarter. Systematic Financial Management LP now owns 117,884 shares of the company’s stock worth $12,680,000 after purchasing an additional 3,962 shares during the last quarter. Principal Financial Group Inc. boosted its holdings in shares of National HealthCare by 2.6% in the 1st quarter. Principal Financial Group Inc. now owns 65,410 shares of the company’s stock valued at $6,070,000 after purchasing an additional 1,671 shares in the last quarter. Finally, First Trust Advisors LP increased its stake in shares of National HealthCare by 75.6% in the 4th quarter. First Trust Advisors LP now owns 47,062 shares of the company’s stock valued at $5,062,000 after purchasing an additional 20,268 shares during the last quarter. Institutional investors own 56.44% of the company’s stock.

Get National HealthCare alerts:

Analysts Set New Price Targets

Separately, Wall Street Zen upgraded National HealthCare from a “buy” rating to a “strong-buy” rating in a research note on Monday, May 12th.

National HealthCare Stock Up 0.5%

Shares of NYSE:NHC opened at $111.97 on Thursday. National HealthCare Co. has a 52-week low of $89.14 and a 52-week high of $137.53. The company has a market capitalization of $1.74 billion, a PE ratio of 14.03 and a beta of 0.58. The company has a debt-to-equity ratio of 0.14, a quick ratio of 1.77 and a current ratio of 1.80. The company has a fifty day moving average of $103.37 and a 200-day moving average of $99.37.

National HealthCare Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th will be issued a $0.64 dividend. This represents a $2.56 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date of this dividend is Tuesday, September 30th. National HealthCare’s dividend payout ratio is presently 38.15%.

About National HealthCare

(Free Report)

National HealthCare Corporation engages in the operation of services to skilled nursing facilities, assisted and independent living facilities, homecare and hospice agencies, and health hospitals. Its skilled nursing facilities offer licensed therapy services, nutrition services, social services, activities, and housekeeping and laundry services, as well as medical services prescribed by physicians; and rehabilitative services, such as physical, speech, respiratory, and occupational therapy for patients recovering from strokes, heart attacks, orthopedic conditions, neurological illnesses, or other illnesses, injuries, or disabilities.

See Also

Want to see what other hedge funds are holding NHC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for National HealthCare Co. (NYSE:NHC – Free Report).

Receive News & Ratings for National HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for National HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.
[Source link]: https://www.etfdailynews.com/2025/08/28/quantbot-technologies-lp-makes-new-investment-in-national-healthcare-co-nhc/


[TITLE]MedaSync announces strategic investment from Omega Healthcare OHI:
[TEXT]
Mon AS X AS Amer Sports

Block Trade

Managers: Morgan Stanley

Priced at: $39.90

4.05M Shares

Special Comments

Exclusive Analysis Locked Proprietary deal commentary available to members only.
[Source link]: https://thefly.com/permalinks/entry.php/id4189228/OHI-MedaSync-announces-strategic-investment-from-Omega-Healthcare


[TITLE]SCWorx Expands Healthcare Data Management Network with New Collaboration:
[TEXT]
Tampa, FL, Aug. 26, 2025 (GLOBE NEWSWIRE) -- SCWorx Corp. (Nasdaq: WORX) today announced a new agreement with a leading healthcare supply chain partner, further strengthening its SaaS data management program.

The partner is a recognized leader in healthcare supply chain consulting, with deep experience helping hospitals unlock cost savings and optimize spend management. The partner also has access to best-in-class products and services at the local, regional, and national levels for virtually every product or service to help hospitals optimize their direct and indirect procurement spend categories.

“This partner drives measurable savings by vetting vendors, analyzing contracts, and leveraging billions in spend through strategic purchasing. They have purchasing partners in all 50 states and are growing every day. All of this helps the partner anticipate, identify, and proactively deliver cost-saving opportunities through cooperative purchasing on an ongoing basis,” said Tim Hannibal, SCWorx CEO. Hannibal added, “The SCWorx Foundation product will help this partner enhance their product line and provide additional value to their healthcare customer. This partner chose SCWorx for its data cleanse, normalization and enrichment service offerings. SCWorx is a valuable data management service partner specifically built to help hospitals in the U.S. better utilize data. This partnership reinforces the unique value SCWorx delivers to hospitals nationwide.”
[Source link]: https://www.globenewswire.com/news-release/2025/08/26/3139426/0/en/SCWorx-Expands-Healthcare-Data-Management-Network-with-New-Collaboration.html

================================================================================

